1-4 of 4
Donald Morris, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Adult Recipients of Matched Related Donor Blood Cell Transplants Given Pretransplant Antithymocyte Globulin Have Less Graft-Versus-Host Disease and Transplant-Related Mortality: Follow-Up of a Matched Pair Analysis.

James A. Russell, FRCP, Loree M. Larratt, MD, A. Robert Turner, MD, M. Ahsan Chaudhry, MD, Oluyeme Jeje, MD, Donald Morris, MD, Christopher Brown, MD, Diana M. Quinlan, BN, Douglas A. Stewart, MD
Journal: Blood
Blood (2006) 108 (11): 2865.
https://doi.org/10.1182/blood.V108.11.2865.2865
Published: 2006
Journal Articles

High Dose Thiotepa, Busulfan, Cyclophosphamide (TBC) and Autologous Hematopoietic Stem Cell Transplantation (ASCT) without Whole Brain Radiotherapy (WBRT) for Primary Central Nervous System Lymphoma (PCNSL).

Douglas A. Stewart, MD, FRCPC, Peter Forsyth, MD, Ahsan Chaudhry, MD, Oluyemi Jeje, MD, Donald Morris, MD, FRCPC, Lynn Savoie, MD, FRCPC, Chris Brown, MD, FRCPC, James R. Russell, MB, FRCPC
Journal: Blood
Blood (2004) 104 (11): 911.
https://doi.org/10.1182/blood.V104.11.911.911
Published: 2004
Journal Articles

A Prospective Phase II Comparison of Stem Cell Source Using Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) RE—Induction, Then High Dose Fludarabine, Busulfan (FLUBU) and Autologous (ASCT) or Allogeneic (AlloSCT) Hematopoietic Blood Stem Cell Transplantation for Mantle Cell (MCL) and Relapsed Low-Grade B-Cell Non-Hodgkin’s Lymphoma (NHL).

Douglas A. Stewart, MD, FRCPC, Michael Voralia, MD, FRCPC, Ahsan Chaudhry, MD, Oluyemi Jeje, MD, Donald Morris, MD, FRCPC, Lynn Savoie, MD, FRCPC, Chris Brown, MD, FRCPC, Wanda Hasagawa, MD, FRCPC, Nizar Bahlis, MD, James R. Russell, MB, BChir, FRCPC
Journal: Blood
Blood (2004) 104 (11): 915.
https://doi.org/10.1182/blood.V104.11.915.915
Published: 2004
Journal Articles

Adult Matched Sibling Blood Cell Transplants (BCT) after Myeloablative Conditioning Incorporating Daily Intravenous (IV) Busulfan (BU) and Low-Dose Antithymocyte Globulin (ATG): Outcomes with Particular Respect to Transplant-Related Mortality (TRM) in 140 Patients.

James A. Russell, FRCP, Ahsan M. Chaudhy, MD, Oluyeme Jeje, MD, Diana Quinlan, RN, Douglas Stewart, MD, Donald Morris, MD, Nizhar J. Bahlis, MD, Lynne Savoie, MD, Christopher B. Brown, MD, Loree Larratt, MD, Michelle Geddes, MD, A. Robert Turner, MD
Journal: Blood
Blood (2004) 104 (11): 2313.
https://doi.org/10.1182/blood.V104.11.2313.2313
Published: 2004